DOCSLIB.ORG

Pharmacy Medical Necessity Guidelines: CNS Stimulant Medications

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Pharmacy Medical Necessity Guidelines: CNS Stimulant Medications Pharmacy Medical Necessity Guidelines: CNS Stimulant Medications Effective: August 10, 2021 Prior Authorization Required √ Type of Review – Care Management Not Covered Type of Review – Clinical Review √ Pharmacy (RX) or Medical (MED) Benefit RX Department to Review RXUM These pharmacy medical necessity guidelines apply to the following: Commercial Products Tufts Health Plan Commercial products – large group plans Tufts Health Plan Commercial products – small group and individual plans Tufts Health Freedom Plan products – large group plans Fax Numbers: Tufts Health Freedom Plan products – small group plans RXUM: 617.673.0988 • CareLinkSM – Refer to CareLink Procedures, Services and Items Requiring Prior Authorization Tufts Health Public Plans Products Tufts Health Direct – A Massachusetts Qualified Health Plan (QHP) (a commercial product) Tufts Health Together – MassHealth MCO Plan and Accountable Care Partnership Plans Tufts Health RITogether – A Rhode Island Medicaid Plan Note: This guideline does not apply to Medicare Members (includes dual eligible Members). OVERVIEW FOOD AND DRUG ADMINISTRATION-APPROVED INDICATIONS The following non-preferred central nervous system (CNS) stimulant medications are indicated for the treatment of attention deficit hyperactivity disorder (ADHD): dexmethylphenidate extended-release 25 mg and 35 mg (Focalin XR), lisdexamfetamine (Vyvanse), methylphenidate transdermal (Daytrana), methylphenidate extended-release 10 mg (Ritalin LA 10 mg), and methylphenidate oral suspension (Quillivant XR). Vyvanse is also indicated for the treatment of moderate to severe binge eating disorder. Please note: Tufts Health Plan recommends the Provider review member-specific medication usage through state(s) Online Prescription Monitoring Program(s). Tufts Health Together Preferred Drug List Status Member Member Age Age Quantity Brand Name* Generic Name –less ≥ 25 yrs Limitations than 24 old yrs old Dyanavel XR amphetamine ER oral suspension PA; QL PA; QL 8 ml/day amphetamine orally disintegrating Evekeo ODT PA PA n/a tablet amphetamine/dextroamphetamine Adderall QL PA; QL 3 tablets/day IR tablets amphetamine/dextroamphetamine 2 Adderall XR QL PA; QL ER capsules capsules/day Focalin XR 5mg, 10mg, 15mg, dexmethylphenidate ER capsules QL PA; QL 1 capsule/day 20mg, 30mg, 40mg Focalin XR dexmethylphenidate ER capsules PA; QL PA; QL 1 capsule/day 25mg, 35mg Focalin dexmethylphenidate IR tablets QL PA; QL 2 tablets/day dextroamphetamine 24HR CR 3 Dexedrine QL PA; QL capsules capsules/day Procentra dextroamphetamine oral solution QL PA; QL 40 ml/day 6010307 1 Pharmacy Medical Necessity Guidelines: ADHD Stimulant Medications Tufts Health Together Preferred Drug List Status Member Member Age Age Quantity Brand Name* Generic Name –less ≥ 25 yrs Limitations than 24 old yrs old Dexedrine/Zenzedi dextroamphetamine IR tablets QL PA; QL 3 tablets/day 5mg, 10mg Vyvanse capsule lisdexamfetamine PA; QL PA; QL 1 capsule/day Desoxyn methamphetamine tablets QL PA; QL 5 tablets/day Adhansia ER methylphenidate ER capsules PA; QL PA; QL 1 tablet/day Metadate CD methylphenidate DR capsules QL PA; QL 1 capsule/day Ritalin LA methylphenidate ER capsules QL PA; QL 1 capsule/day 20mg, 30mg, 40mg Ritalin LA methylphenidate ER capsules PA; QL PA; QL 1 capsule/day 10mg, 60mg Methylin Tablets methylphenidate chewable tablets QL PA; QL 3 tablets/day Quillivant XR methylphenidate ER oral PA; QL PA; QL 12ml/day Suspension suspension Methylin Solution methylphenidate oral solution QL PA; QL 30ml/day Ritalin methylphenidate IR tablets QL PA; QL 3 tablets/day Methylphenidate ER methylphenidate ER tablets QL PA; QL 1 tablet/day 10mg Ritalin SR 20mg methylphenidate ER tablets QL PA; QL 1 tablet/day Concerta methylphenidate ER tablets QL PA; QL 1 tablet/day 18 mg, 27 mg, 54 mg Concerta 36mg methylphenidate ER tablets QL PA; QL 2 tablets/day Daytrana methylphenidate transdermal PA; QL PA; QL 1 patch/day COVERAGE GUIDELINES The plan may authorize coverage of a CNS stimulant medication for Members when all of the following criteria are met: Age-Specific Criteria Members 25 years of age and older The plan may authorize coverage of a preferred or non-preferred stimulant medication for Members 25 years of age or older when all of the following age-specific criteria are met. Additionally, if the medication is non-preferred, the non-preferred stimulant medication criteria must also be met. 1. Member has one of the following diagnoses*: a) Attention Deficit Hyperactivity Disorder (ADHD) b) Binge-eating disorder (Vyvanse only) b) Narcolepsy c) Depressive condition in which the stimulant will be used as an augmenting agent with concomitant antidepressant medication(s), and bipolar disease, thyroid disease, cardiovascular conditions have been ruled out d) Traumatic Brain Injury e) Documented excessive sleepiness associated with a documented diagnosis of one of the following chronic medical conditions • Depression • Chronic fatigue syndrome • Multiple sclerosis • Organic brain disorder • Obstructive Sleep Apnea/Hypopnea Syndrome • Parkinson’s Disease 2 Pharmacy Medical Necessity Guidelines: ADHD Stimulant Medications Note: The Plan recommends the Provider reviews Member-specific medication usage through the state’s Online Prescription Monitoring Program. *Vyvanse will only be approved for the treatment of binge-eating disorder or ADHD, while Daytrana will only be approved for the treatment of ADHD AND 2. For immediate-release products: a) The provider indicates there is no concern with active substance abuse or diversion AND b) The provider indicates clinical rationale of therapy with an immediate-release formulation instead of long-acting/extended-release formulations Non-Preferred CNS Stimulant Criteria The plan may authorization coverage of a non-preferred stimulant for Members less than 25 years of age when all of the following medication-specific criteria are met. Additionally, if the Member is 25 years of age or older, the age-specific criteria listed above must be met before applying the medication-specific criteria listed below: Amphetamine extended-release oral solution (Dyanavel XR) and Amphetamine orally disintegrating tablet (Evekeo ODT) 1. Documentation the Member has failed a course of therapy with generic amphetamine/dextroamphetamine extended-release capsules and at least one additional generic CNS ADHD stimulant Dexmethylphenidate 25 mg and 35 mg extended-release (Focalin XR) 1. Documentation the Member failed a course of therapy with at least two alternative generic extended- release methylphenidate medications, such as generic formulations of Concerta, Metadate CD , Focalin XR (20 mg, 40 mg) or Ritalin LA Lisdexamfetamine capsule (Vyvanse) Approval is limited to the diagnosis of ADHD and BED and is not available for narcolepsy, traumatic brain injury, or depression 1. For the diagnosis of ADHD, a) Documentation the member has tried and failed therapy with at least two generic stimulant medications with different active ingredients (i.e., methylphenidate product, amphetamine product) 2. For the diagnosis of binge-eating disorder, a) Documentation the Member has tried and failed therapy with at least two alternative generic non- stimulant therapies (e.g., cognitive behavioral therapy, antidepressant therapy, mood stabilizers) Methylphenidate suspension (Quillivant XR) 1. Documentation the Member has failed a course of therapy with generic methylphenidate oral solution and at least one additional generic CNS ADHD stimulant Methylphenidate 10 and 60 mg extended-release (Ritalin LA) capsules 1. Documentation the Member has failed a course of therapy with an alternative generic methylphenidate extended-release medication of comparable strength (e.g., Metadate CD 10 mg, Metadate CD 60 mg, methylphenidate extended-release 10 mg tablets) Methylphenidate extended-release capsules (Adhansia XR) 1. Documentation that the Member has failed a course of therapy with an alternative generic methylphenidate extended-release medication and a least one additional generic CNS ADHD stimulant Methylphenidate transdermal (Daytrana) 1. Documented diagnosis of ADHD AND 2. Documentation the member has failed a course of therapy with at least two generic alternative CNS ADHD stimulants Upon renewal for all authorized CNS stimulant medications, 1. Documentation the Member has had an office visit and has been re-assessed for this condition within the past year, and continued therapy with this medication is considered medically necessary LIMITATIONS 1. Approval duration will be limited to 2 years. 3 Pharmacy Medical Necessity Guidelines: ADHD Stimulant Medications 2. Quantity limitations that apply to the stimulant medications are listed in the table in the Overview section. 3. Lisdexamfetamine (Vyvanse) will only be approved for the treatment of ADHD and binge-eating disorder 4. Methylphenidate transdermal (Daytrana) will only be approved for the treatment of ADHD 5. Requests for brand-name products, with AB-rated generics, will be reviewed according to Non- covered Medications criteria. 6. Samples, free goods, or similar offerings of the requested medication do not qualify for an established clinical response or exception, but will be considered on an individual basis for prior authorization. CODES None REFERENCES 1. Adhansia XR (methylphenidate extended-release) [prescribing information]. Stamford, CT: Adlon Therapeutics, LP; June 2021. 2. Adzenys ER (amphetamine) oral suspension [prescribing information]. Grand Prairie, TX: Neos Therapeutics; September 2017. 3. Adzenys
Load more

Recommended publications
  • Methylphenidate Hydrochloride
    Application for Inclusion to the 22nd Expert Committee on the Selection and Use of Essential Medicines: METHYLPHENIDATE HYDROCHLORIDE December 7, 2018 Submitted by: Patricia Moscibrodzki, M.P.H., and Craig L. Katz, M.D. The Icahn School of Medicine at Mount Sinai Graduate Program in Public Health New York NY, United States Contact: [email protected] TABLE OF CONTENTS Page 3 Summary Statement Page 4 Focal Point Person in WHO Page 5 Name of Organizations Consulted Page 6 International Nonproprietary Name Page 7 Formulations Proposed for Inclusion Page 8 International Availability Page 10 Listing Requested Page 11 Public Health Relevance Page 13 Treatment Details Page 19 Comparative Effectiveness Page 29 Comparative Safety Page 41 Comparative Cost and Cost-Effectiveness Page 45 Regulatory Status Page 48 Pharmacoepial Standards Page 49 Text for the WHO Model Formulary Page 52 References Page 61 Appendix – Letters of Support 2 1. Summary Statement of the Proposal for Inclusion of Methylphenidate Methylphenidate (MPH), a central nervous system (CNS) stimulant, of the phenethylamine class, is proposed for inclusion in the WHO Model List of Essential Medications (EML) & the Model List of Essential Medications for Children (EMLc) for treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) under ICD-11, 6C9Z mental, behavioral or neurodevelopmental disorder, disruptive behavior or dissocial disorders. To date, the list of essential medications does not include stimulants, which play a critical role in the treatment of psychotic disorders. Methylphenidate is proposed for inclusion on the complimentary list for both children and adults. This application provides a systematic review of the use, efficacy, safety, availability, and cost-effectiveness of methylphenidate compared with other stimulant (first-line) and non-stimulant (second-line) medications.
    [Show full text]
  • Comparison of the Inhibitory and Excitatory Effects of ADHD Medications Methylphenidate and Atomoxetine on Motor Cortex
    Neuropsychopharmacology (2006) 31, 442–449 & 2006 Nature Publishing Group All rights reserved 0893-133X/06 $30.00 www.neuropsychopharmacology.org Comparison of the Inhibitory and Excitatory Effects of ADHD Medications Methylphenidate and Atomoxetine on Motor Cortex ,1 2 3 1 1 4 Donald L Gilbert* , Keith R Ridel , Floyd R Sallee , Jie Zhang , Tara D Lipps and Eric M Wassermann 1 2 Division of Neurology, Cincinnati Children’s Hospital Medical Center, University of Cincinnati, Cincinnati, OH, USA; University of Cincinnati 3 4 School of Medicine, Cincinnati, OH, USA; Division of Psychiatry, University of Cincinnati, Cincinnati, OH, USA; Brain Stimulation Unit, National Institute of Neurological Disorders and Stroke, Bethesda, MD, USA Stimulant and norepinephrine (NE) reuptake inhibitor medications have different effects at the neuronal level, but both reduce symptoms of attention deficit hyperactivity disorder (ADHD). To understand their common physiologic effects and thereby gain insight into the neurobiology of ADHD treatment, we compared the effects of the stimulant methylphenidate (MPH) and NE uptake inhibitor atomoxetine (ATX) on inhibitory and excitatory processes in human cortex. Nine healthy, right-handed adults were given a single, oral dose of 30 mg MPH and 60 mg ATX at visits separated by 1 week in a randomized, double-blind crossover trial. We used paired and single transcranial magnetic stimulation (TMS) of motor cortex to measure conditioned and unconditioned motor-evoked potential amplitudes at inhibitory (3 ms) and facilitatory (10 ms) interstimulus intervals (ISI) before and after drug administration. Data were analyzed with repeated measures, mixed model regression. We also analyzed our findings and the published literature with meta-analysis software to estimate treatment effects of stimulants and NE reuptake inhibitors on these TMS measures.
    [Show full text]
  • Synthetic Cathinones ("Bath Salts")
    Synthetic Cathinones ("Bath Salts") What are synthetic cathinones? Synthetic cathinones, more commonly known as "bath salts," are synthetic (human- made) drugs chemically related to cathinone, a stimulant found in the khat plant. Khat is a shrub grown in East Africa and southern Arabia, and people sometimes chew its leaves for their mild stimulant effects. Synthetic variants of cathinone can be much stronger than the natural product and, in some cases, very dangerous (Baumann, 2014). In Name Only Synthetic cathinone products Synthetic cathinones are marketed as cheap marketed as "bath salts" should substitutes for other stimulants such as not be confused with products methamphetamine and cocaine, and products such as Epsom salts that people sold as Molly (MDMA) often contain synthetic use during bathing. These cathinones instead (s ee "Synthetic Cathinones bathing products have no mind- and Molly" on page 3). altering ingredients. Synthetic cathinones usually take the form of a white or brown crystal-like powder and are sold in small plastic or foil packages labeled "not for human consumption." Also sometimes labeled as "plant food," "jewelry cleaner," or "phone screen cleaner," people can buy them online and in drug paraphernalia stores under a variety of brand names, which include: Flakka Bloom Cloud Nine Lunar Wave Vanilla Sky White Lightning Scarface Image courtesy of www.dea.gov/pr/multimedia- library/image-gallery/bath-salts/bath-salts04.jpg Synthetic Cathinones • January 2016 • Page 1 How do people use synthetic cathinones? People typically swallow, snort, smoke, or inject synthetic cathinones. How do synthetic cathinones affect the brain? Much is still unknown about how synthetic cathinones affect the human brain.
    [Show full text]
  • What Every Clinician Should Know Before Starting a Patient on Meds
    CARING FOR CHILDREN WITH ADHD: A RESOURCE TOOLKIT FOR CLINICIANS, 2ND EDITION Basic Facts: What Every Clinician Should Know Before Starting a Patient on Medication Studies have shown that treatment for attention-deficit/ • If you reach the maximum recommended dose without • hyperactivity disorder (ADHD) with medication is effective in noticeable improvement in symptoms, try a different stimulant treating the symptoms of ADHD alone or in combination with medication class. Approximately 80% of children will respond to behavioral interventions. at least 1 of the 2 stimulant classes tried. • Stimulant medications also improve academic productivity but • When changing medications, be careful about the dose not cognitive abilities or academic skills. equivalence of different stimulant medication classes; in general, equivalent doses for dexmethylphenidate and Stimulants can help reduce oppositional, aggressive, impulsive, • amphetamine-based stimulants are approximately half of a and delinquent behaviors in some children. methylphenidate dose. Several types of medications are Food and Drug Administration Non-stimulant medications may require 2 or more weeks to see • (FDA)-approved for the treatment of ADHD. • effects, so you should titrate up more slowly than you would • Stimulant medications: methylphenidate, dexmethylphenidate, for stimulant medications. Obtaining follow-up rating scales is dextroamphetamine, mixed amphetamine salts, even more important than for stimulant medications because lisdexamfetamine changes are more gradual. • Non-stimulant medications: atomoxetine, and extended-release • Managing side effects effectively can improve adherence to and guanfacine and clonidine satisfaction with stimulant medications. When choosing which stimulant and dose to start first, consider • Common side effects to discuss with families include • stomachache, headache, decreased appetite, sleep problems, Family preference and experience with the medication, including • and behavioral rebound.
    [Show full text]
  • Do You Know... Cocaine
    Do You Know... Street names: blow, C, coke, crack, flake, freebase, rock, snow Cocaine What is cocaine? Cocaine is a stimulant drug. Stimulants make people feel more alert and energetic. Cocaine can also make people feel euphoric, or “high.” Pure cocaine was first isolated from the leaves of the coca bush in 1860. Researchers soon discovered that cocaine numbs whatever tissues it touches, leading to its use as a local anesthetic. Today, we mostly use synthetic anesthetics, rather than cocaine. In the 1880s, psychiatrist Sigmund Freud wrote scientific papers that praised cocaine as a treatment for many ailments, including depression and alcohol and opioid addiction. After this, cocaine became widely and legally available in patent medicines and soft drinks. As cocaine use increased, people began to discover its dangers. In 1911, Canada passed laws restricting the importation, manufacture, sale and possession of cocaine. The use of 1/4 © 2003, 2010 CAMH | www.camh.ca cocaine declined until the 1970s, when it became known How does cocaine make you feel? for its high cost, and for the rich and glamorous people How cocaine makes you feel depends on: who used it. Cheaper “crack” cocaine became available · how much you use in the 1980s. · how often and how long you use it · how you use it (by injection, orally, etc.) Where does cocaine come from? · your mood, expectation and environment Cocaine is extracted from the leaves of the Erythroxylum · your age (coca) bush, which grows on the slopes of the Andes · whether you have certain medical or psychiatric Mountains in South America.
    [Show full text]
  • A Brief Overview of Psychiatric Pharmacotherapy
    A Brief Overview of Psychiatric Pharmacotherapy Joel V. Oberstar, M.D. Chief Executive Officer Disclosures • Some medications discussed are not approved by the FDA for use in the population discussed/described. • Some medications discussed are not approved by the FDA for use in the manner discussed/described. • Co-Owner: – PrairieCare and PrairieCare Medical Group – Catch LLC Disclaimer The contents of this handout are for informational purposes only and are not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical or psychiatric condition. Never disregard professional/medical advice or delay in seeking it because of something you have read in this handout. Material in this handout may be copyrighted by the author or by third parties; reasonable efforts have been made to give attribution where appropriate. Caveat Regarding the Role of Medication… Neuroscience Overview Mind Over Matter, National Institute on Drug Abuse, National Institutes of Health. Available at: http://teens.drugabuse.gov/mom/index.asp. http://medicineworld.org/images/news-blogs/brain-700997.jpg Neuroscience Overview Mind Over Matter, National Institute on Drug Abuse, National Institutes of Health. Available at: http://teens.drugabuse.gov/mom/index.asp. Neurotransmitter Receptor Source: National Institute on Drug Abuse Common Diagnoses and Associated Medications • Psychotic Disorders – Antipsychotics • Bipolar Disorders – Mood Stabilizers, Antipsychotics, & Antidepressants • Depressive Disorders – Antidepressants • Anxiety Disorders – Antidepressants & Anxiolytics • Attention Deficit Hyperactivity Disorder – Stimulants, Antidepressants, 2-Adrenergic Agents, & Strattera Classes of Medications • Anti-depressants • Stimulants and non-stimulant alternatives • Anti-psychotics (a.k.a.
    [Show full text]
  • 7 Nicotinic Receptor Agonists
    CORE Metadata, citation and similar papers at core.ac.uk Provided by PubMed Central The Open Medicinal Chemistry Journal, 2010, 4, 37-56 37 Open Access 7 Nicotinic Receptor Agonists: Potential Therapeutic Drugs for Treatment of Cognitive Impairments in Schizophrenia and Alzheimer’s Disease Jun Toyohara, and Kenji Hashimoto* Division of Clinical Neuroscience, Chiba University Center for Forensic Mental Health, Chiba, Japan Abstract: Accumulating evidence suggests that 7 nicotinic receptors (7 nAChRs), a subtype of nAChRs, play a role in the pathophysiology of neuropsychiatric diseases, including schizophrenia and Alzheimer’s disease (AD). A number of psychopharmacological and genetic studies shown that 7 nAChRs play an important role in the deficits of P50 auditory evoked potential in patients with schizophrenia, and that 7 nAChR agonists would be potential therapeutic drugs for cognitive impairments associated with P50 deficits in schizophrenia. Furthermore, some studies have demonstrated that 7 nAChRs might play a key role in the amyloid- (A)-mediated pathology of AD, and that 7 nAChR agonists would be potential therapeutic drugs for A deposition in the brains of patients with AD. Interestingly, the altered expression of 7 nAChRs in the postmortem brain tissues from patients with schizophrenia and AD has been reported. Based on all these findings, selective 7 nAChR agonists can be considered potential therapeutic drugs for cognitive impairments in both schizophrenia and AD. In this article, we review the recent research into the role of 7 nAChRs in the pathophysiology of these diseases and into the potential use of novel 7 nAChR agonists as therapeutic drugs. Keywords: 7 Nicotinic receptors, Cognition, Schizophrenia, Alzheimer’s disease.
    [Show full text]
  • Phencyclidine: an Update
    Phencyclidine: An Update U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES • Public Health Service • Alcohol, Drug Abuse and Mental Health Administration Phencyclidine: An Update Editor: Doris H. Clouet, Ph.D. Division of Preclinical Research National Institute on Drug Abuse and New York State Division of Substance Abuse Services NIDA Research Monograph 64 1986 DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Alcohol, Drug Abuse, and Mental Health Administratlon National Institute on Drug Abuse 5600 Fishers Lane Rockville, Maryland 20657 For sale by the Superintendent of Documents, U.S. Government Printing Office Washington, DC 20402 NIDA Research Monographs are prepared by the research divisions of the National lnstitute on Drug Abuse and published by its Office of Science The primary objective of the series is to provide critical reviews of research problem areas and techniques, the content of state-of-the-art conferences, and integrative research reviews. its dual publication emphasis is rapid and targeted dissemination to the scientific and professional community. Editorial Advisors MARTIN W. ADLER, Ph.D. SIDNEY COHEN, M.D. Temple University School of Medicine Los Angeles, California Philadelphia, Pennsylvania SYDNEY ARCHER, Ph.D. MARY L. JACOBSON Rensselaer Polytechnic lnstitute National Federation of Parents for Troy, New York Drug Free Youth RICHARD E. BELLEVILLE, Ph.D. Omaha, Nebraska NB Associates, Health Sciences Rockville, Maryland REESE T. JONES, M.D. KARST J. BESTEMAN Langley Porter Neuropsychiatric lnstitute Alcohol and Drug Problems Association San Francisco, California of North America Washington, D.C. DENISE KANDEL, Ph.D GILBERT J. BOTV N, Ph.D. College of Physicians and Surgeons of Cornell University Medical College Columbia University New York, New York New York, New York JOSEPH V.
    [Show full text]
  • Prescription Stimulants
    Prescription Stimulants What are prescription stimulants? Prescription stimulants are medicines generally used to treat attention-deficit hyperactivity disorder (ADHD) and narcolepsy— uncontrollable episodes of deep sleep. They increase alertness, attention, and energy. What are common prescription stimulants? • dextroamphetamine (Dexedrine®) • dextroamphetamine/amphetamine combination product (Adderall®) • methylphenidate (Ritalin®, Concerta®). Photo by ©iStock.com/ognianm Popular slang terms for prescription stimulants include Speed, Uppers, and Vitamin R. How do people use and misuse prescription stimulants? Most prescription stimulants come in tablet, capsule, or liquid form, which a person takes by mouth. Misuse of a prescription stimulant means: Do Prescription Stimulants Make You • taking medicine in a way or dose Smarter? other than prescribed Some people take prescription stimulants to • taking someone else’s medicine try to improve mental performance. Teens • taking medicine only for the effect it and college students sometimes misuse causes—to get high them to try to get better grades, and older adults misuse them to try to improve their When misusing a prescription stimulant, memory. Taking prescription stimulants for people can swallow the medicine in its reasons other than treating ADHD or normal form. Alternatively, they can crush narcolepsy could lead to harmful health tablets or open the capsules, dissolve the powder in water, and inject the liquid into a effects, such as addiction, heart problems, vein. Some can also snort or smoke the or psychosis. powder. Prescription Stimulants • June 2018 • Page 1 How do prescription stimulants affect the brain and body? Prescription stimulants increase the activity of the brain chemicals dopamine and norepinephrine. Dopamine is involved in the reinforcement of rewarding behaviors.
    [Show full text]
  • MDPV) (Street Names: “Bath Salts,” “Ivory Wave,” “Plant Fertilizer,” “Vanilla Sky,” “Energy-1”) December 2019
    Drug Enforcement Administration Diversion Control Division Drug & Chemical Evaluation Section 3,4-Methylenedioxypyrovalerone (MDPV) (Street Names: “bath salts,” “Ivory Wave,” “plant fertilizer,” “Vanilla Sky,” “Energy-1”) December 2019 Introduction: reported for stimulants such as cocaine and methamphetamine. 3,4-Methylenedioxypyrovalerone (MDPV) is a designer MDPV has been reported to induce subjective effects in drug of the phenethylamine class. MDPV is structurally humans similar to those induced by cocaine, amphetamine, and related to cathinone, an active alkaloid found in the khat MDMA. The subjective effects induced by substituted plant, 3,4-methylenedioxymethamphetamine (MDMA), cathinones are feelings of empathy, stimulation, alertness, methamphetamine, and other schedule I phenethylamines. euphoria, and awareness of senses. Other effects reported from MDPV, like some other substances in this class, is a central the use of MDPV were tachycardia, hypertension, nervous system (CNS) stimulant. MDPV is also reported to vasoconstriction, and sweating. MDPV has also been reported have hallucinogenic effects. MDPV has been identified in to cause intense, prolonged panic attacks in users. Repeat products that are falsely marketed as “bath salts,” “plant users have reported bouts of psychosis and a craving or a strong food,” and “research chemicals” and is sold over the Internet desire or urge to use again. There have been reports of deaths and at local retail shops. in which MDPV was either implicated or ruled as the cause of death. Licit Uses: Users of MDPV anecdotally reported that they take 25 mg MDPV is not approved for medical use in the United or less per session. The duration of the subjective effects is States.
    [Show full text]
  • Sitmulants (Cocaine and Amphetamines)
    Treatment of Acute Intoxication and Withdrawal from Drugs of Abuse Adapted or excerpted from: The Textbook of Substance Abuse Treatment, second edition. Editors: Marc Galanter, MD and Herbert D Kleber, MD Sitmulants (Cocaine and Amphetamines) “The intoxicated person may show signs of hyperawareness, hypersexuality, hypervigialance, and psychomotor agitation. Often, the symptoms of stimulant-induced intoxication resemble mania. The intoxicated person should be monitored by the medical staff until the symptoms of intoxication diminish. If the intoxication does not return to baseline level within 24 hours, mania may be present, and treatment for manic discorder may be required. With increased dosage and duration of administration, stimulants can also produce a state of mental confusion and excitement know as stimulant delirium. Delirium is associated with becoming disoriented and confused as well as anxious and fearful. Extreme medical caution is needed when treating delirium because such symptoms may indicate stimulant overdose. For instance, patients addicted to crack cocaine who over-dose need careful monitoring for seizures, cardiac arrhythmias, stroke, and pulmonary complication. Overdose management has been reviewed in detail (see Gay, 1982: Ann Emerg Med 11:562-572), but more recently a syndrome of hyperthermia and agitation has been described that resembles neuroleptic malignant syndrome. Standard pharmaological management of overdose includes neuroleptics, but high doses of benzodiazepines may be safer alternatives for controlling the delirium and agitation because neuroleptics will worsen the hyperthermia in some cases of overdose and lead to fatality. Acute use of benzodiazepines can also help minimize the need for physical restraints. During high-dose stimulant use, often seen during binge episodes, individuals can experience stimulant- induced psychosis characterized by delusions, paranoid thinking and stereotyped compulsive behavior.
    [Show full text]
  • 2 Agonist ABT-894 in Adults with ADHD
    Neuropsychopharmacology (2013) 38, 405–413 & 2013 American College of Neuropsychopharmacology. All rights reserved 0893-133X/13 www.neuropsychopharmacology.org A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of a4b2 Agonist ABT-894 in Adults with ADHD ,1 1 1 1 1,3 1,4 Earle E Bain* , Weining Robieson , Yili Pritchett , Tushar Garimella , Walid Abi-Saab , George Apostol , 2 1,5 James J McGough and Mario D Saltarelli 1 2 Clinical Development, Abbott Laboratories, Abbott Park, IL, USA; Semel Institute for Neuroscience and Behavior, David Geffen School of Medicine, UCLA, Los Angeles, CA, USA Dysregulation of the neuronal nicotinic acetylcholine receptor (NNR) system has been implicated in attention-deficit/hyperactivity disorder (ADHD), and nicotinic agonists improve attention across preclinical species and humans. Hence, a randomized, double-blind, placebo-controlled, crossover study was designed to determine the safety and efficacy of a novel a4b2 NNR agonist (ABT-894 (3-(5,6- dichloro-pyridin-3-yl)-1(S),5 (S)-3,6-diazabicyclo[3.2.0]heptane)) in adults with ADHD. Participants (N 243) were randomized to one ¼ of four dose regimens of ABT-894 (1, 2, and 4 mg once daily (QD)) or 4 mg twice daily (BID) or the active comparator atomoxetine (40 mg BID) vs placebo for 28 days. Following a 2-week washout period, participants crossed over to the alternative treatment condition (active or placebo) for an additional 28 days. Primary efficacy was based on an investigator-rated Conners’ Adult ADHD Rating Scale (CAARS:Inv) Total score at the end of each 4-week treatment period. Additional secondary outcome measures were assessed.
    [Show full text]